From these I have hypothesised additional forward actions that may likely see open label maintenance trials as hinted at in earnings call transcripts as well as commercialisation of VK2735 in 2029 and advancement of the DACRA pipeline
Large-scale randomised controlled trials such as the STEP programme (semaglutide) and SCALE trials (liraglutide) reported pancreatitis as an uncommon adverse event (occurring in 0.1-1% of patients), with no clear signal for increased risk compared to placebo
The assay has been validated according to CLSI, FDA, and EMA guidelines
Nardone OM, de Sire R, Petito V, Testa A, Villani G, Scaldaferri F, et al
This lower risk was principally driven by a significant decrease in the incidence of nonfatal stroke (39 %) and a nonsignificant decrease in nonfatal MI (26 %) but without significant difference in the rate of CV death
The results also emphasized a return to earlier pre-treatment baseline levels one week after antimicrobial cessation